Share this to:

Support & Insight for the Autumn of Life

Aducanumab Looks Good in Earliest Stages of Alzheimer’s

VIDEO + ARTICLE:

Aducanumab for Alzheimer’s is showing encouraging results as Phase 3 trials roll out. See how this new immunotherapy is treating Alzheimer’s at Georgetown University.


This year, Biogen Inc. is executing two Phase 3 clinical trials for aducanumab in Alzheimer’s disease.

Continued below video…

Two global, placebo-controlled studies named ENGAGE and EMERGE are designed to evaluate the efficacy and safety of aducanumab in slowing cognitive impairment and the progression of disability in people with early Alzheimer’s disease (AD).

“Since the initial readout of our Phase 1b study, we have accelerated our aducanumab clinical program so that we can more fully characterize and confirm the benefit-risk profile of this investigational treatment for Alzheimer’s disease,” said Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer at Biogen. “We continue to work with our colleagues around the world to advance the study of aducanumab.”

Aducanumab (BIIB037) is an investigational compound being developed for the treatment of AD. Aducanumab is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune’s technology platform called Reverse Translational Medicine (RTM). Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.

Aducanumab is thought to target aggregated forms of beta amyloid including soluble oligomers and insoluble fibrils deposited into the amyloid plaque in the brain of AD patients. Based on pre-clinical and interim Phase 1b data, treatment with aducanumab has been shown to reduce amyloid plaque levels.




RELATED VIDEO + ARTICLE:

Biogen Exceeds Expectations, Helps Clear Alzheimer’s Plaque

SOURCES:

  • Georgetown University
  • Biogen
Subscribe
Notify of
guest

6 Comments
Inline Feedbacks
View all comments
Unknown
Unknown
6 years ago

I'm glad they may have something promising but what about those of us with moderate to severe.

Unknown
Unknown
Reply to  Unknown
6 years ago

There are nutraceutical supplements,still under study, with dozens of well fundamented scientific research articles,about research in neuron cells cultures,in animal models and in human beings,that shows some good results as described in scientific articles.And it nutraceuticals,in a fast and easy way,looks to lowers not only the betamyloid and tau accumulation,but looks to works controlling what upstreams,leads to it accumulations of betamyloid and tau that are the biochemical,molecular, metabolical and brain energy disorders,that looks to be the triggers and looks to perpetuates that disorders.The problem is that such nutraceutical supplements that, maybe, could works as SUPPORT THERAPY in all stages of AD and in all stages of most types of others dementias,do not have none patent and are very very cheap.And substances that in some way works,but do not have patent and are cheap,are not attractive to some pharma companies…

Unknown
Unknown
Reply to  Unknown
6 years ago

This comment has been removed by the author.

Unknown
Unknown
6 years ago

We can find some information about failure wirh the substance aducanumab in the medical site Medpage Today,searching in the Google with the words: "Aducanumab 6-mg Dose Disappoints lack of cognitive improvements"

Anonymous
Anonymous
6 years ago

You might want to google Anavex Life Sciences. They also had two on-going trials, for Alzheimer's showing promising results. Lot of buzz around their 2-73 drug.

Anonymous
Anonymous
6 years ago

Will this drug also work for tau associated with CTE? My husband was diagnosed at 65 with early onset senile dementia attributed to multiple sports concussions and has been taking aricept for the last 5 years.

B. Berger

B. Berger

Visit Our Pages On:

Welcome

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Related

a133-DNA-W160.jpeg
TREM2 Helps Break the Alzheimer's Code
See Dr. David Samati explain the important connection between the TREM2 gene and Alzheimer's disease. Read about its ...
1071.jpeg
ClockMe Computerized Dementia Self-Test Created at Georgia Tech
See Georgia Tech's simple-to-use computer program that allows adults to screen themselves for early signs of dementia.
a413-Stemcells-W160.jpeg
Princeton Fast-Tracks New Path for Treating Alzheimer's
Princeton University set its sights on preventing amyloid-beta plaque, the most notorious culprit behind Alzheimer's....

Books

Amazon Books
6
0
Would love your thoughts, please comment.x
()
x
News to Get at the Truth

Subscribe To Our Weekly Newsletter

Enjoy thought-provoking videos & articles
News to Get at the Truth

Subscribe To Our Weekly Newsletter